Saphnelo
anifrolumab
APPROVED
Drug Profile
ModalityAntibody
RouteIV
Therapy AreaR&I
Launch2021-08-02
US LOE2033-08-01
Peak Sales Est$1500M
Formulations[{"id":"saphnelo-iv","doses":"300mg","route":"IV","device":"IV infusion","setting":"CLINIC","frequen
Mechanism: Type I IFN receptor antagonist
Expert: Human IgG1κ monoclonal antibody targeting IFNAR1 subunit that blocks signaling of all type I interferons implicated in SLE pathogenesis.
Everyday: Blocks interferon signals that drive autoimmune inflammation in lupus.
Targets: ["IFNAR1"]
Revenue History
| Period | Revenue ($M) |
|---|
| 2023 | $385M |
| 2024 | $541M |
| Q1 2025 | $165M |
Programs (1)
| Indication | Stage | Key Study | Regional Status |
|---|
| SLE | APPROVED | TULIP-2 | [{"stage":"APPROVED","region":"US","approval_date":"2021-08-02"},{"stage":"APPRO |
Upcoming Catalysts (2)
Saphnelo - Lupus Nephritis - Ph3 - Topline
H2 2026
Saphnelo - Systemic Sclerosis - Ph3 - Topline
H2 2026
Notes
Type I IFN receptor antibody for SLE.
Data from Supabase · Updated 2026-03-24